Disc Medicine Prices Upsized $450 Million Stock Offering at $75 Per Share

Disc Medicine, Inc. (IRON) priced an upsized underwritten public offering of 6 million common shares at $75.00 per share, expecting aggregate gross proceeds of $450 million. The clinical-stage biopharmaceutical company granted underwriters a 30-day option to buy up to 0.9 million additional shares at the public offering price, less discounts and commissions. The offering is expected to close on October 22, 2026, subject to customary conditions. Net proceeds, combined with existing cash and marketable securities, will fund research and clinical development of current and future pipeline candidates, including ongoing development of Bitopertin for Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), plus commercialization planning, pre-launch activities, working capital and general corporate purposes. Jefferies, Leerink Partners, Morgan Stanley and Cantor are joint book-running managers; LifeSci Capital, BMO Capital Markets and H.C. Wainwright & Co. are co-managers. IRON closed Tuesday's trade at $79.48, up 0.70%, within a 52-week range of $40.00 to $99.50. The stock was down 0.79% at $78.85 in overnight trading.